GE Healthcare announced at this month's Society of Nuclear Medicine meeting the development of a system to help produce a derivative of the fluorine positron radioisotope. The 18F-F2 isotope is a critical starting point for the production of F-DOPA,
GE Healthcare announced at this month's Society of Nuclear Medicine meeting the development of a system to help produce a derivative of the fluorine positron radioisotope. The 18F-F2 isotope is a critical starting point for the production of F-DOPA, which has shown potential in diagnosing Parkinson's disease. The new technology, part of GE's PETtrace cyclotron offering, evolved from a collaboration with Imanet, a joint venture between Amersham and leading PET research centers. The 18F-F2 option boosts production capacity by nearly a factor of four, according to GE. This will increase the availability of this compound for use in research while laying the groundwork for wider use if F-DOPA becomes clinically viable.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.